Accès gratuit
Med Sci (Paris)
Volume 17, Numéro 12, Décembre 2001
Page(s) 1343 - 1348
Section Mini-Synthèses
Publié en ligne 15 décembre 2001
  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 : 57–70.
  2. Werner H, Le Roith D. New concepts in regulation and function of the insulin-like growth factors : implications for understanding normal growth and neoplasia. Cell Mol Life Sci 2000; 57 : 932–42.
  3. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulinlike growth factor receptor. Cell Mol Life Sci 2000; 57 : 1050–93.
  4. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21 : 215–44.
  5. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58 : 1159–64.
  6. Andrews DW, Resnicoff M, Flanders AE,et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19 : 2189–200.
  7. Weiss B, Davidkova G, Zhou LW. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999; 55 : 334–58.
  8. Myers KJ, Dean NM. Sensible use of antisense : how to use oligonucleotides as research tools. Trends Pharmacol Sci 2000; 21 : 19–23.
  9. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259 : 94–7.
  10. Resnicoff M, Sell C, Rubini M,et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54 : 2218–22.
  11. Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P, Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 1997; 94 : 5854–9.
  12. Lafarge-Frayssinet C, Duc HT, Frayssinet C,et al. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression. Cancer Gene Ther 1997; 4 : 276–85.
  13. Lee CT, Wu S, Gabrilovich D,et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996; 56 : 3038–41.
  14. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998; 58 : 5432–8.
  15. Wraight CJ, White PJ, McKean SC,et al. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol 2000; 18 : 521–6.
  16. Akhtar S, Hughes MD, Khan A,et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000; 44 : 3–21.
  17. Resnicoff M. Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Int J Mol Med 1998; 1 : 883–8.
  18. Beutler A, Banck MS, Aguzzi A, Wedekind D, Hedrich HJ. Curing rat glioblastoma : immunotherapy or graft rejection ? Science 1997; 276 : 20–21.
  19. Upegui-Gonzalez LC, François JC, Ly A, Trojan J. The approach of triple helix formation in control of gene expression and the treatment of tumors expressing IGF-I. Adv Exp Med Biol 2000; 465 : 319–32.
  20. Liu Y, Wang H, Zhao J,et al. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. Cancer Gene Ther 2000; 7 : 456–65.
  21. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000; 7 : 384–95.
  22. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor : expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49 : 243–52.
  23. Reiss K, Tu X, Romano G, Peruzzi F, Wang JY, Baserga R. Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors. Clin Cancer Res 2001; 7 : 2134–44.
  24. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 1994; 91 : 2181–5.
  25. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53 : 1102–6.
  26. Navab R, Chevet E, Authier F, Di Guglielmo GM, Bergeron JJ, Brodt P. Inhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functions. J Biol Chem 2001; 276 : 13644–9.
  27. Delafontaine P, Meng XP, Ku L, Du J. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem 1995; 270 : 14383–8.
  28. Ly A, Duc HT, Kalamarides M,et al. Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 2001; 54 : 230–9.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.